BCV
BMRN icon

Banque Cantonale Vaudoise’s BioMarin Pharmaceuticals BMRN Stock Holding History

Banque Cantonale Vaudoise’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$904K Hold
16,000
– – 0.03% 398
2025
Q4 		$951K Hold
16,000
– – 0.03% 364
2025
Q3 		$867K Hold
16,000
– – 0.03% 376
2025
Q2 		$880K Hold
16,000
– – 0.04% 378
2025
Q1 		$1.13M Buy
+16,000
New +$1.08M 0.05% 335
2024
Q3 		$1.13M Sell
16,000
-350
-2% -$29.3K 0.05% 300
2024
Q2 		$1.35M Hold
16,350
– – 0.05% 301
2024
Q1 		$1.43M Sell
16,350
-414
-2% -$37.1K 0.06% 302
2023
Q4 		$1.62M Sell
16,764
-2,870
-15% -$254K 0.07% 265
2023
Q3 		$1.74M Sell
19,634
-536
-3% -$47.7K 0.09% 190
2023
Q2 		$1.75M Sell
20,170
-50
-0.2% -$4.71K 0.08% 212
2023
Q1 		$1.97M Sell
20,220
-3,800
-16% -$394K 0.1% 204
2022
Q4 		$2.48M Buy
24,020
+3,742
+18% +$351K 0.13% 157
2022
Q3 		$1.72M Buy
20,278
+522
+3% +$46.5K 0.1% 199
2022
Q2 		$1.64M Sell
19,756
-700
-3% -$55.7K 0.08% 225
2022
Q1 		$1.58M Hold
20,456
– – 0.07% 282
2021
Q4 		$1.81M Sell
20,456
-962
-4% -$79.4K 0.07% 266
2021
Q3 		$1.66M Buy
21,418
+15,500
+262% +$1.22M 0.07% 274
2021
Q2 		$494K Sell
5,918
-2,415
-29% -$191K 0.02% 594
2021
Q1 		$628K Sell
8,333
-5,778
-41% -$472K 0.03% 482
2020
Q4 		$1.24M Buy
14,111
+1,414
+11% +$112K 0.07% 254
2020
Q3 		$964K Sell
12,697
-2,064
-14% -$209K 0.06% 267
2020
Q2 		$1.82M Buy
14,761
+7,557
+105% +$751K 0.13% 156
2020
Q1 		$608K Sell
7,204
-416
-5% -$35.8K 0.05% 319
2019
Q4 		$644K Buy
+7,620
New +$576K 0.04% 386

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Banque Cantonale Vaudoise's BMRN Position: Q1 2026 in Review

Banque Cantonale Vaudoise held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 16,000 shares worth $904K. The position accounts for 0.03% of the portfolio, ranked #398.

Banque Cantonale Vaudoise first reported a position in BMRN in Q4 2019 and has held it in 25 quarters since. The position peaked at $2.48M in Q4 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Banque Cantonale Vaudoise held 16,000 shares of BioMarin Pharmaceuticals worth $904K as of Q1 2026.
  • Banque Cantonale Vaudoise left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.03% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #398 holding.
  • Banque Cantonale Vaudoise first reported a position in BioMarin Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Banque Cantonale Vaudoise's BioMarin Pharmaceuticals position peaked at $2.48M in Q4 2022.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.